This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Julias, J. G.
Right arrow Articles by Pathak, V. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Julias, J. G.
Right arrow Articles by Pathak, V. K.

 Previous Article  |  Next Article 

J. Virol., 06 1997, 4254-4263, Vol 71, No. 6
Copyright © 1997, American Society for Microbiology

The antiretrovirus drug 3'-azido-3'-deoxythymidine increases the retrovirus mutation rate

JG Julias, T Kim, G Arnold and VK Pathak
Department of Biochemistry, Mary Babb Randolph Cancer Center, West Virginia University, Morgantown 26506, USA.

It was previously observed that the nucleoside analog 5-azacytidine increased the spleen necrosis virus (SNV) mutation rate 13-fold in one cycle of retrovirus replication (V. K. Pathak and H. M. Temin, J. Virol. 66:3093-3100, 1992). Based on this observation, we hypothesized that nucleoside analogs used as antiviral drugs may also increase retrovirus mutation rates. We sought to determine if 3'-azido-3'- deoxythymidine (AZT), the primary treatment for human immunodeficiency virus type 1 (HIV-1) infection, increases the retrovirus mutation rate. Two assays were used to determine the effects of AZT on retrovirus mutation rates. The strategy of the first assay involved measuring the in vivo rate of inactivation of the lacZ gene in one replication cycle of SNV- and murine leukemia virus-based retroviral vectors. We observed 7- and 10-fold increases in the SNV mutant frequency following treatment of target cells with 0.1 and 0.5 microM AZT, respectively. The murine leukemia virus mutant frequency increased two- and threefold following treatment of target cells with 0.5 and 1.0 microM AZT, respectively. The second assay used an SNV-based shuttle vector containing the lacZ alpha gene. Proviruses were recovered as plasmids in Escherichia coli, and the rate of inactivation of lacZ alpha was measured. The results indicated that treatment of target cells increased the overall mutation rate two- to threefold. DNA sequence analysis of mutant proviruses indicated that AZT increased both the deletion and substitution rates. These results suggest that AZT treatment of HIV-1 infection may increase the degree of viral variation and alter virus evolution or pathogenesis.


This article has been cited by other articles:

  • Dapp, M. J., Clouser, C. L., Patterson, S., Mansky, L. M. (2009). 5-Azacytidine Can Induce Lethal Mutagenesis in Human Immunodeficiency Virus Type 1. J. Virol. 83: 11950-11958 [Abstract] [Full Text]  
  • Bampi, C., Bibillo, A., Wendeler, M., Divita, G., Gorelick, R. J., Le Grice, S. F. J., Darlix, J.-L. (2006). Nucleotide Excision Repair and Template-independent Addition by HIV-1 Reverse Transcriptase in the Presence of Nucleocapsid Protein. J. Biol. Chem. 281: 11736-11743 [Abstract] [Full Text]  
  • Nikolenko, G. N., Palmer, S., Maldarelli, F., Mellors, J. W., Coffin, J. M., Pathak, V. K. (2005). Mechanism for nucleoside analog-mediated abrogation of HIV-1 replication: Balance between RNase H activity and nucleotide excision. Proc. Natl. Acad. Sci. USA 102: 2093-2098 [Abstract] [Full Text]  
  • Nikolenko, G. N., Svarovskaia, E. S., Delviks, K. A., Pathak, V. K. (2004). Antiretroviral Drug Resistance Mutations in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Increase Template-Switching Frequency. J. Virol. 78: 8761-8770 [Abstract] [Full Text]  
  • Voronin, Y. A., Pathak, V. K. (2004). Frequent Dual Initiation in Human Immunodeficiency Virus-Based Vectors Containing Two Primer-Binding Sites: a Quantitative In Vivo Assay for Function of Initiation Complexes. J. Virol. 78: 5402-5413 [Abstract] [Full Text]  
  • Mansky, L. M., Pearl, D. K., Gajary, L. C. (2002). Combination of Drugs and Drug-Resistant Reverse Transcriptase Results in a Multiplicative Increase of Human Immunodeficiency Virus Type 1 Mutant Frequencies. J. Virol. 76: 9253-9259 [Abstract] [Full Text]  
  • Zhang, W.-H., Svarovskaia, E. S., Barr, R., Pathak, V. K. (2002). Y586F mutation in murine leukemia virus reverse transcriptase decreases fidelity of DNA synthesis in regions associated with adenine-thymine tracts. Proc. Natl. Acad. Sci. USA 99: 10090-10095 [Abstract] [Full Text]  
  • Zhang, W.-h., Hwang, C. K., Hu, W.-S., Gorelick, R. J., Pathak, V. K. (2002). Zinc Finger Domain of Murine Leukemia Virus Nucleocapsid Protein Enhances the Rate of Viral DNA Synthesis in Vivo. J. Virol. 76: 7473-7484 [Abstract] [Full Text]  
  • Beasley, B. E., Hu, W.-S. (2002). cis-Acting Elements Important for Retroviral RNA Packaging Specificity. J. Virol. 76: 4950-4960 [Abstract] [Full Text]  
  • Janini, M., Rogers, M., Birx, D. R., McCutchan, F. E. (2001). Human Immunodeficiency Virus Type 1 DNA Sequences Genetically Damaged by Hypermutation Are Often Abundant in Patient Peripheral Blood Mononuclear Cells and May Be Generated during Near-Simultaneous Infection and Activation of CD4+ T Cells. J. Virol. 75: 7973-7986 [Abstract] [Full Text]  
  • Dang, Q., Hu, W.-S. (2001). Effects of Homology Length in the Repeat Region on Minus-Strand DNA Transfer and Retroviral Replication. J. Virol. 75: 809-820 [Abstract] [Full Text]  
  • Halvas, E. K., Svarovskaia, E. S., Pathak, V. K. (2000). Role of Murine Leukemia Virus Reverse Transcriptase Deoxyribonucleoside Triphosphate-Binding Site in Retroviral Replication and In Vivo Fidelity. J. Virol. 74: 10349-10358 [Abstract] [Full Text]  
  • Mansky, L. M., Bernard, L. C. (2000). 3'-Azido-3'-Deoxythymidine (AZT) and AZT-Resistant Reverse Transcriptase Can Increase the In Vivo Mutation Rate of Human Immunodeficiency Virus Type 1. J. Virol. 74: 9532-9539 [Abstract] [Full Text]  
  • Svarovskaia, E. S., Delviks, K. A., Hwang, C. K., Pathak, V. K. (2000). Structural Determinants of Murine Leukemia Virus Reverse Transcriptase That Affect the Frequency of Template Switching. J. Virol. 74: 7171-7178 [Abstract] [Full Text]  
  • Halvas, E. K., Svarovskaia, E. S., Pathak, V. K. (2000). Development of an In Vivo Assay To Identify Structural Determinants in Murine Leukemia Virus Reverse Transcriptase Important for Fidelity. J. Virol. 74: 312-319 [Abstract] [Full Text]  
  • Argentini, C, La Sorsa, V, Bruni, R, D'Ugo, E, Giuseppetti, R, Rapicetta, M (1999). Hepadnavirus evolution and molecular strategy of adaptation in a new host. J. Gen. Virol. 80: 617-626 [Abstract]  
  • Julias, J. G., Pathak, V. K. (1998). Deoxyribonucleoside Triphosphate Pool Imbalances In Vivo Are Associated with an Increased Retroviral Mutation Rate. J. Virol. 72: 7941-7949 [Abstract] [Full Text]  
  • Certo, J. L., Shook, B. F., Yin, P. D., Snider, J. T., Hu, W.-S. (1998). Nonreciprocal Pseudotyping: Murine Leukemia Virus Proteins Cannot Efficiently Package Spleen Necrosis Virus-Based Vector RNA. J. Virol. 72: 5408-5413 [Abstract] [Full Text]  
  • Anderson, J. A., Bowman, E. H., Hu, W.-S. (1998). Retroviral Recombination Rates Do Not Increase Linearly with Marker Distance and Are Limited by the Size of the Recombining Subpopulation. J. Virol. 72: 1195-1202 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»